SCHEMBL3099869

SCHEMBL3099869

O=C(N1CCC(c2ccc(F)cc2)CC1)N1CCC(C(=O)O)(c2ccc(F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.49
CYP3A4 P08684 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.45
APP P05067 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CCR1 P32246 1/20 0.43
PARP10 Q53GL7 1/20 0.43
RORC P51449 1/20 0.43
TET3 O43151 2/20 0.42
KMT2A Q03164 2/20 0.42
FBXL19 Q6PCT2 2/20 0.42
CXXC5 Q7LFL8 2/20 0.42
KDM2B Q8NHM5 2/20 0.42
CXXC4 Q9H2H0 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098845 0.85 HSD11B1 (0.59) HSD11B1NPC1KCNH2HRH3TET3
SCHEMBL28036178 0.83 RAB9A (0.55) HSD11B1NPC1RAB9AATMKCNH2
SCHEMBL6960087 0.79 CYP3A4 (0.48) HSD11B1CYP3A4NPC1RAB9AAPP
SCHEMBL378652 0.79 AKR1C3 (0.59) TET3KMT2AFBXL19CXXC5KDM2B
SCHEMBL3790649 0.79 KMT2A (0.51) HSD11B1CYP3A4APPCYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6963690 0.78 CYP3A4 (0.47) HSD11B1CYP3A4NPC1RAB9A
SCHEMBL5767423 0.78 TACR1 (0.64) CYP2D6KCNH2KMT2ATACR1
SCHEMBL6494230 0.78 TACR1 (0.64) CYP2D6KCNH2KMT2ATACR1
SCHEMBL5767429 0.78 TACR1 (0.64) CYP2D6KCNH2KMT2ATACR1
SCHEMBL350223 0.77 HSD11B1 (0.77) HSD11B1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 HSD11B1 3638/4885CYP3A4 1349/4885NPC1 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.